Guard Therapeutics International AB (publ)
STO: GUARD.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Tobias Larsson Agervald
- Employees
- 12
- Headquarters
- Stockholm, Sweden
- IPO year
- 2013
- Market cap
- SEK 24.0M
- Website
- https://guardtherapeutics.com
Loading GUARD…
Loading profile data…Frequently asked questions about GUARD
What does Guard Therapeutics International AB (publ) (GUARD.ST) do?
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company w...
Where does GUARD.ST trade?
Guard Therapeutics International AB (publ) (GUARD.ST) trades on the Stockholm Stock Exchange.
What sector is GUARD.ST in?
Guard Therapeutics International AB (publ) (GUARD.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Guard Therapeutics International AB (publ)?
Tobias Larsson Agervald is the chief executive officer of Guard Therapeutics International AB (publ) (GUARD.ST).
Where is Guard Therapeutics International AB (publ) headquartered?
Guard Therapeutics International AB (publ) is headquartered in Sweden.
Does GUARD.ST pay a dividend?
Guard Therapeutics International AB (publ) (GUARD.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GUARD.ST go public?
Guard Therapeutics International AB (publ) (GUARD.ST) completed its initial public offering in 2013.